|Dr. John R. Melki BSc, Ph.D.||MD, CEO & Exec. Director||483.01k||N/A||N/A|
|Mr. Peter L. Manley CPA||CFO & Company Sec.||285.37k||N/A||N/A|
|Mr. Michael Anton Aicher BSc, M.B.A., MBA||Exec. Director of US Operations & Exec. Director||161.55k||N/A||1960|
|Mr. Christopher M. Abbott||Founder & Chairman Emeritus||N/A||N/A||N/A|
|Dr. Douglas S. Millar BSc, Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Mr. Jackson Jones B.Sc.||Director of Global Sales & Marketing||N/A||N/A||N/A|
Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in Australia, Asia Pacific, North America, Europe, the Middle East, and Africa. It designs and manufactures a suite of real-time polymerase chain reaction-based products for detection of infectious diseases under EasyScreen brand name. The company also provides MDx 3Base platform technology that enables hospital and pathology laboratories to screen for a range of infectious pathogens. In addition, it offers detection kits for gastrointestinal infections, respiratory pathogens, sexual health, anti-microbial resistance, meningitis, and tropical disease. The company was incorporated in 2001 and is headquartered in Newtown, Australia.
Genetic Signatures Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.